Fereshteh Asgharzadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fereshteh Asgharzadeh has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Majid Khazaei
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
20 shared publications - Amir Avan
Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
13 shared publications Mahmoud Hosseini
Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
8 shared publicationsRahimeh Bargi
Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
8 shared publications- Seyed Mahdi Hassanian
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
8 shared publications - Farimah Beheshti
Department of Physiology, School of Medicine, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
7 shared publications
Latest Publications
- Open Access
- 31 July 2024
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 14 (3) , 513-523
Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities
Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.
- 31 July 2024
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 14 (3) , 513-523
Open AccessNanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities
Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.
- Open Access
- 1 July 2024
- Published by Apex Publishing in Physiology and Pharmacology
- Vol. 28 (2) , 169-179
The evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice
Introduction: Intestinal colitis, also known as ulcerative colitis, is an inflammatory bowel disease characterized by long-term inflammation and ulcers in the gastrointestinal tract. It has been suggested that the mucosal expression of angiotensin II (AT-II) is increased in colitis. This study aimed to examine the potential therapeutic effects of combination ...
- 1 July 2024
- Published by Apex Publishing in Physiology and Pharmacology
- Vol. 28 (2) , 169-179
Open AccessThe evaluation of synergistic effects of combination therapy with sulfasalazine and angiotensin-converting enzyme inhibitor in the treatment of experimental colitis in mice
Introduction: Intestinal colitis, also known as ulcerative colitis, is an inflammatory bowel disease characterized by long-term inflammation and ulcers in the gastrointestinal tract. It has been suggested that the mucosal expression of angiotensin II (AT-II) is increased in colitis. This study aimed to examine the potential therapeutic effects of combination ...
- Open Access
- 24 June 2024
- Published by Elsevier in Translational Oncology
- Vol. 47, 102039
Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growth
- 24 June 2024
- Published by Elsevier in Translational Oncology
- Vol. 47, 102039
Open AccessPeroxisome proliferator-activated receptors: Key regulators of tumor progression and growth
- Open Access
- 25 April 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 600-611
The therapeutic potential of angiotensin-converting enzyme inhibitor enalapril to ameliorate muscle atrophy in a murine model
Muscle atrophy due to limb immobilization and inactivity is a common consequence of many diseases and treatment processes. One of the systems activated in inflammatory conditions is the renin-angiotensin system (RAS). The present study was conducted with the aim of investigating the effects of one of the angiotensin-converting enzyme (ACE) inhibitors, enalapril, on improving muscle atrophy caused by immobility. The study was conducted in three groups: a control, an atrophy, and an atrophy group treated with enalapril on Balb/c mice. After tying a splint to cause atrophy in one of the legs, daily treatment with enalapril intraperitoneally (dissolved in DMSO) at a dose of 10 mg/kg/day was done for 7 days. On the eighth day, the splint was opened and half of the mice were evaluated. Then, in the recovery phase, treatment with enalapril was continued in the remaining mice for 10 days without a splint. At the end of each phase, the mice were examined for the muscle strength of the lower limb muscles, and histological and biochemical analyses were subsequently carried out. The tissue level of the oxidative stress index MDA was evaluated, which showed a significantly lower level in the enalapril group compared to the atrophy group (*P<0.1). Also, inflammatory factors in the enalapril group showed a decrease compared to the atrophy group. The strength of four limbs in the mice of the treatment group (-18.36 ± 1.70 %) was significantly higher than that of the atrophy group (-30.33 ± 3 %) at the end of the atrophy phase and also after 10 days of recovery. The results suggest that the use of enalapril that reduces the activation of angiotensin II-dependent pro-oxidant and pro-inflammatory pathways may improve the functional disorder and muscle necrosis in the murine model of muscle atrophy.
- 25 April 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 600-611
Open AccessThe therapeutic potential of angiotensin-converting enzyme inhibitor enalapril to ameliorate muscle atrophy in a murine model
Muscle atrophy due to limb immobilization and inactivity is a common consequence of many diseases and treatment processes. One of the systems activated in inflammatory conditions is the renin-angiotensin system (RAS). The present study was conducted with the aim of investigating the effects of one of the angiotensin-converting enzyme (ACE) inhibitors, enalapril, on improving muscle atrophy caused by immobility. The study was conducted in three groups: a control, an atrophy, and an atrophy group treated with enalapril on Balb/c mice. After tying a splint to cause atrophy in one of the legs, daily treatment with enalapril intraperitoneally (dissolved in DMSO) at a dose of 10 mg/kg/day was done for 7 days. On the eighth day, the splint was opened and half of the mice were evaluated. Then, in the recovery phase, treatment with enalapril was continued in the remaining mice for 10 days without a splint. At the end of each phase, the mice were examined for the muscle strength of the lower limb muscles, and histological and biochemical analyses were subsequently carried out. The tissue level of the oxidative stress index MDA was evaluated, which showed a significantly lower level in the enalapril group compared to the atrophy group (*P<0.1). Also, inflammatory factors in the enalapril group showed a decrease compared to the atrophy group. The strength of four limbs in the mice of the treatment group (-18.36 ± 1.70 %) was significantly higher than that of the atrophy group (-30.33 ± 3 %) at the end of the atrophy phase and also after 10 days of recovery. The results suggest that the use of enalapril that reduces the activation of angiotensin II-dependent pro-oxidant and pro-inflammatory pathways may improve the functional disorder and muscle necrosis in the murine model of muscle atrophy.
- Open Access
- 23 September 2023
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 31 (2) , 193-203
Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer
Background Several studies have shown that the TGF-β signaling pathway plays a critical role in colorectal cancer (CRC) pathogenesis. The aim of the current study is to investigate the therapeutic potential of Vactosertib (EW-7197), a selective inhibitor of TGF-β receptor type I, either alone or in combination with the standard first-line chemotherapeutic treatment, 5-Fluorouracil (5-FU), in CRC progression in both cellular and animal models. Methods Real-Time PCR, Zymography, enzyme-linked immunosorbent assay (ELISA), Hematoxylin and Eosin (H&E) tissue staining, and Flow cytometry techniques were applied to determine the anti-tumor properties of this novel TGF-β inhibitor in in vitro (CT-26 cell line) and in vivo (inbred BALB/C mice) samples. Results Our findings showed that Vactosertib decreased cell proliferation and induced spheroid shrinkage. Moreover, this inhibitor suppressed the cell cycle and its administration either alone or in combination with 5-FU induced apoptosis by regulating the expression of p53 and BAX proteins. It also improved 5-FU anti-cancer effects by decreasing the tumor volume and weight, increasing tumor necrosis, and regulating tumor fibrosis and inflammation in an animal model. Vactosertib also enhanced the inhibitory effect of 5-FU on invasive behavior of CRC cells by upregulating the expression of E-cadherin and inhibiting MMP-9 enzymatic activity. Conclusion This study demonstrating the potent anti-tumor effects of Vactosertib against CRC progression. Our results clearly suggest that this inhibitor could be a promising agent reducing CRC tumor progression when administered either alone or in combination with standard treatment in CRC patients. Graphical abstract
- 23 September 2023
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 31 (2) , 193-203
Open AccessVactosertib potently improves anti-tumor properties of 5-FU for colon cancer
Background Several studies have shown that the TGF-β signaling pathway plays a critical role in colorectal cancer (CRC) pathogenesis. The aim of the current study is to investigate the therapeutic potential of Vactosertib (EW-7197), a selective inhibitor of TGF-β receptor type I, either alone or in combination with the standard first-line chemotherapeutic treatment, 5-Fluorouracil (5-FU), in CRC progression in both cellular and animal models. Methods Real-Time PCR, Zymography, enzyme-linked immunosorbent assay (ELISA), Hematoxylin and Eosin (H&E) tissue staining, and Flow cytometry techniques were applied to determine the anti-tumor properties of this novel TGF-β inhibitor in in vitro (CT-26 cell line) and in vivo (inbred BALB/C mice) samples. Results Our findings showed that Vactosertib decreased cell proliferation and induced spheroid shrinkage. Moreover, this inhibitor suppressed the cell cycle and its administration either alone or in combination with 5-FU induced apoptosis by regulating the expression of p53 and BAX proteins. It also improved 5-FU anti-cancer effects by decreasing the tumor volume and weight, increasing tumor necrosis, and regulating tumor fibrosis and inflammation in an animal model. Vactosertib also enhanced the inhibitory effect of 5-FU on invasive behavior of CRC cells by upregulating the expression of E-cadherin and inhibiting MMP-9 enzymatic activity. Conclusion This study demonstrating the potent anti-tumor effects of Vactosertib against CRC progression. Our results clearly suggest that this inhibitor could be a promising agent reducing CRC tumor progression when administered either alone or in combination with standard treatment in CRC patients. Graphical abstract
- 14 August 2023
- Published by Taylor & Francis
- p. 297-311
Turmeric (Curcuma longa) and Applications to Cancer Studies
Cyclin-dependent kinase
- 14 August 2023
- Published by Taylor & Francis
- p. 297-311
Turmeric (Curcuma longa) and Applications to Cancer Studies
Cyclin-dependent kinase
- Open Access
Therapeutic Potential of Targeting the Cytochrome P450 Enzymes Using Lopinavir/Ritonavir in Colorectal Cancer: A Study in Monolayers, Spheroids and In Vivo Models
Cytochrome P450 (CYP450) enzyme has been shown to be expressed in colorectal cancer (CRC) and its dysregulation is linked to tumor progression and a poor prognosis. Here we investigated the therapeutic potential of targeting CYP450 using lopinavir/ritonavir in CRC. The integrative systems biology method and RNAseq were utilized to investigate the differential levels of genes associated with patients with colorectal cancer. The antiproliferative activity of lopinavir/ritonavir was evaluated in both monolayer and 3-dimensional (3D) models, followed by wound-healing assays. The effectiveness of targeting CYP450 was examined in a mouse model, followed by histopathological analysis, biochemical tests (MDA, SOD, thiol, and CAT), and RT-PCR. The data of dysregulation expressed genes (DEG) revealed 1268 upregulated and 1074 down-regulated genes in CRC. Among the top-score genes and dysregulated pathways, CYPs were detected and associated with poor prognosis of patients with CRC. Inhibition of CYP450 reduced cell proliferation via modulating survivin, Chop, CYP13a, and induction of cell death, as detected by AnnexinV/PI staining. This agent suppressed the migratory behaviors of cells by induction of E-cadherin. Moreover, lopinavir/ritonavir suppressed tumor growth and fibrosis, which correlated with a reduction in SOD/thiol levels and increased MDA levels. Our findings illustrated the therapeutic potential of targeting the CYP450 using lopinavir/ritonavir in colorectal cancer, supporting future investigations on this novel therapeutic approach for the treatment of CRC.
Open AccessTherapeutic Potential of Targeting the Cytochrome P450 Enzymes Using Lopinavir/Ritonavir in Colorectal Cancer: A Study in Monolayers, Spheroids and In Vivo Models
Cytochrome P450 (CYP450) enzyme has been shown to be expressed in colorectal cancer (CRC) and its dysregulation is linked to tumor progression and a poor prognosis. Here we investigated the therapeutic potential of targeting CYP450 using lopinavir/ritonavir in CRC. The integrative systems biology method and RNAseq were utilized to investigate the differential levels of genes associated with patients with colorectal cancer. The antiproliferative activity of lopinavir/ritonavir was evaluated in both monolayer and 3-dimensional (3D) models, followed by wound-healing assays. The effectiveness of targeting CYP450 was examined in a mouse model, followed by histopathological analysis, biochemical tests (MDA, SOD, thiol, and CAT), and RT-PCR. The data of dysregulation expressed genes (DEG) revealed 1268 upregulated and 1074 down-regulated genes in CRC. Among the top-score genes and dysregulated pathways, CYPs were detected and associated with poor prognosis of patients with CRC. Inhibition of CYP450 reduced cell proliferation via modulating survivin, Chop, CYP13a, and induction of cell death, as detected by AnnexinV/PI staining. This agent suppressed the migratory behaviors of cells by induction of E-cadherin. Moreover, lopinavir/ritonavir suppressed tumor growth and fibrosis, which correlated with a reduction in SOD/thiol levels and increased MDA levels. Our findings illustrated the therapeutic potential of targeting the CYP450 using lopinavir/ritonavir in colorectal cancer, supporting future investigations on this novel therapeutic approach for the treatment of CRC.
- 12 June 2023
- Published by Taylor & Francis
- p. 145-159
Black Cumin (Nigella sativa)
Herbal medicine has gained a lot of attention in recent years, and it’s becoming more popular as alternatives to chemical drugs. Medicinal herbs have a positive impact on the prevention and treatment of a wide range of ailments, according to several lines of evidence. Nigella sativa (NS) has been linked to a number of pharmacological effects. Nigella sativa’s constituents, including nigellicine, nigellidine, thymoquinone, dithymoquinone, thymol and carvacrol, have been linked to its biological effects. Furthermore, a significant body of evidence indicates that NS has extremely few side effects, without serious toxicity. More lately, this valuable herbal plant has gotten a lot of attention, and researchers in pre-clinical and clinical studies are investigating to find out whether it can help with health problems. The effects of NS and its compounds on cardiovascular disease are discussed in this chapter. NS and its constituents were found to have favorable cardiovascular benefits. These benefits were most likely attributable to NS anti-inflammatory, antioxidant, anti-apoptotic and anti-fibrotic properties. Taken together, NS and its constituents appear to have therapeutic potential in cardiovascular disorders.
- 12 June 2023
- Published by Taylor & Francis
- p. 145-159
Black Cumin (Nigella sativa)
Herbal medicine has gained a lot of attention in recent years, and it’s becoming more popular as alternatives to chemical drugs. Medicinal herbs have a positive impact on the prevention and treatment of a wide range of ailments, according to several lines of evidence. Nigella sativa (NS) has been linked to a number of pharmacological effects. Nigella sativa’s constituents, including nigellicine, nigellidine, thymoquinone, dithymoquinone, thymol and carvacrol, have been linked to its biological effects. Furthermore, a significant body of evidence indicates that NS has extremely few side effects, without serious toxicity. More lately, this valuable herbal plant has gotten a lot of attention, and researchers in pre-clinical and clinical studies are investigating to find out whether it can help with health problems. The effects of NS and its compounds on cardiovascular disease are discussed in this chapter. NS and its constituents were found to have favorable cardiovascular benefits. These benefits were most likely attributable to NS anti-inflammatory, antioxidant, anti-apoptotic and anti-fibrotic properties. Taken together, NS and its constituents appear to have therapeutic potential in cardiovascular disorders.
- 11 April 2023
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 37 (6)
Fabrication of magnetic nanocomposite as responsive drug delivery vehicle for cervical cancer therapy
The development of carriers for drug delivery faces significant challenges from a therapeutic perspective. The present study presents an innovative nanocarrier based on combination of functionalized magnetic nanocomposite nano‐chitosan and cisplatin. Hydrophobic drugs such as cisplatin could be delivered using magnetic nanoparticles modified with biocompatible copolymers. This study aimed to determine the antitumor effects of free cisplatin enhancement in cervical cancer cells using cisplatin‐encapsulated Fe3O4@SiO2@N‐Chit‐FA. An additional layer of nanochitosan was coated on top of the magnetic nanocomposite to increase its stability in aqueous solutions. Biocompatibility and cytotoxicity of Fe3O4@SiO2@N‐Chit‐FA‐ciscomplex were evaluated against the cervical cancer animal model in C57BL6 mice. An external magnetic field was used to test the in‐vivo uptake and distribution of Fe3O4@SiO2@N‐Chit‐FA‐cisin tumor cells. The results showed that the released drug would induce its effects on a specific target area when an external magnetic field was applied, and Fe3O4@SiO2@N‐Chit‐FA‐ciscan suppress tumor growth more than cisplatin alone via induction of tumor necrosis. Overall, Fe3O4@SiO2@N‐Chit‐FA nanocomposites hold great potential for use in targeted nanomedicine to deliver bio‐functional molecules.
- 11 April 2023
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 37 (6)
Fabrication of magnetic nanocomposite as responsive drug delivery vehicle for cervical cancer therapy
The development of carriers for drug delivery faces significant challenges from a therapeutic perspective. The present study presents an innovative nanocarrier based on combination of functionalized magnetic nanocomposite nano‐chitosan and cisplatin. Hydrophobic drugs such as cisplatin could be delivered using magnetic nanoparticles modified with biocompatible copolymers. This study aimed to determine the antitumor effects of free cisplatin enhancement in cervical cancer cells using cisplatin‐encapsulated Fe3O4@SiO2@N‐Chit‐FA. An additional layer of nanochitosan was coated on top of the magnetic nanocomposite to increase its stability in aqueous solutions. Biocompatibility and cytotoxicity of Fe3O4@SiO2@N‐Chit‐FA‐ciscomplex were evaluated against the cervical cancer animal model in C57BL6 mice. An external magnetic field was used to test the in‐vivo uptake and distribution of Fe3O4@SiO2@N‐Chit‐FA‐cisin tumor cells. The results showed that the released drug would induce its effects on a specific target area when an external magnetic field was applied, and Fe3O4@SiO2@N‐Chit‐FA‐ciscan suppress tumor growth more than cisplatin alone via induction of tumor necrosis. Overall, Fe3O4@SiO2@N‐Chit‐FA nanocomposites hold great potential for use in targeted nanomedicine to deliver bio‐functional molecules.